TVRD
Tvardi Therapeutics, Inc.

314
Mkt Cap
$53.55M
Volume
490,299.00
52W High
$43.65
52W Low
$5.57
PE Ratio
-0.33
TVRD Fundamentals
Price
$5.71
Prev Close
$6.17
Open
$6.09
50D MA
$29.38
Beta
-0.00
Avg. Volume
60,286.76
EPS (Annual)
-$46.60
P/B
1.63
Rev/Employee
$713,700.00
Loading...
Loading...
News
all
press releases
Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Tvardi (TVRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·6d ago
News Placeholder
More News
News Placeholder
TVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
TVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics TVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on...
PR Newswire·7d ago
News Placeholder
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.
Zacks·8d ago
News Placeholder
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. (Tvardi or the Company) (NASDAQ: TVRD). Faruqi & Faruqi is a leading...
Business Wire·8d ago
News Placeholder
Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today?
The company said that its investigational drug did not meet its goal in a study, and no statistically significant differences between placebo and treatment arms were observed after preliminary review of exploratory efficacy.
Stocktwits·9d ago
News Placeholder
Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat...
Business Wire·9d ago

Latest TVRD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.